Exscientia PLC
NASDAQ:EXAI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.99
7.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Exscientia PLC
Exscientia PLC
Cash from Financing Activities
Exscientia PLC
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Cash from Financing Activities
-£3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$519.9m
|
CAGR 3-Years
58%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£2.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exscientia PLC
Glance View
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.
See Also
What is Exscientia PLC's Cash from Financing Activities?
Cash from Financing Activities
-3.4m
GBP
Based on the financial report for Dec 31, 2023, Exscientia PLC's Cash from Financing Activities amounts to -3.4m GBP.
What is Exscientia PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
31%
Over the last year, the Cash from Financing Activities growth was 31%.
You don't have any saved screeners yet
